Clovis Oncology, Inc. Costs and Expenses
Clovis Oncology, Inc. reported Costs and Expenses of $74.90 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2022-11-09
- Clovis Oncology, Inc. costs and expenses for the quarter ending 2022-09-30 was $74.90M, a 21.47% decline year-over-year.
- Clovis Oncology, Inc. costs and expenses for the quarter ending 2022-06-30 was $91.52M, a 3.05% decline year-over-year.
- Clovis Oncology, Inc. costs and expenses for the quarter ending 2022-03-31 was $84.61M, a 11.93% decline year-over-year.
- Clovis Oncology, Inc. costs and expenses for the quarter ending 2021-12-31 was $88.68M, a 18.10% decline year-over-year.
- Clovis Oncology, Inc. costs and expenses for fiscal 2021 was $374.52M, a 19.75% decline from fiscal 2020.
- Clovis Oncology, Inc. costs and expenses for fiscal 2020 was $466.71M, a 10.21% decline from fiscal 2019.
- Clovis Oncology, Inc. costs and expenses for fiscal 2019 was $519.75M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2022-09-30 | $74.90M 10-Q · filed 2022-11-09 | $166.42M derived: sum of 2 quarters · filed 2022-11-09 | $251.03M 10-Q · filed 2022-11-09 | $339.71M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $91.52M 10-Q · filed 2022-08-08 | $176.13M 10-Q · filed 2022-08-08 | $264.81M derived: sum of 3 quarters · filed 2022-08-08 | $360.19M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $84.61M 10-Q · filed 2022-05-05 | $173.28M derived: sum of 2 quarters · filed 2022-05-05 | $268.67M derived: sum of 3 quarters · filed 2022-11-09 | $363.07M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | $88.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $184.06M derived: sum of 2 quarters · filed 2022-11-09 | $278.46M derived: sum of 3 quarters · filed 2022-11-09 | $374.52M 10-K · filed 2022-02-24 |
| 2021-09-30 | $95.38M 10-Q · filed 2022-11-09 | $189.78M derived: sum of 2 quarters · filed 2022-11-09 | $285.85M 10-Q · filed 2022-11-09 | $394.13M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $94.40M 10-Q · filed 2022-08-08 | $190.47M 10-Q · filed 2022-08-08 | $298.75M derived: sum of 3 quarters · filed 2022-08-08 | $410.07M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $96.06M 10-Q · filed 2022-05-05 | $204.34M derived: sum of 2 quarters · filed 2022-05-05 | $315.66M derived: sum of 3 quarters · filed 2022-05-05 | $438.20M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $108.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $219.60M derived: sum of 2 quarters · filed 2022-02-24 | $342.13M derived: sum of 3 quarters · filed 2022-02-24 | $466.71M 10-K · filed 2022-02-24 |
| 2020-09-30 | $111.32M 10-Q · filed 2021-11-03 | $233.85M derived: sum of 2 quarters · filed 2021-11-03 | $358.43M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $122.53M 10-Q · filed 2021-08-04 | $247.11M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $124.58M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $519.75M 10-K · filed 2022-02-24 |